The current definition, epidemiology, animal models and a novel therapeutic strategy for aspiration pneumonia

Respir Investig. 2022 Jan;60(1):45-55. doi: 10.1016/j.resinv.2021.09.012. Epub 2021 Nov 12.

Abstract

In the 21st century, aspiration pneumonia (ASP) is very common in older patients, and has a high mortality rate. ASP is diagnosed following confirmation of inflammatory findings in the lungs and overt aspiration or the existence of dysphagia. It is dominant in hospitalized community-acquired pneumonia (CAP), nursing and healthcare-associated pneumonia (NHCAP), and hospital-acquired pneumonia (HAP). The incidence of ASP is increasing every year. The human and experimental animal data revealed that micro-aspiration due to dysphagia during the night is the central mechanism of ASP. Therefore, the precise assessment of swallowing function is the key to diagnose ASP. From a therapeutic point of view, an appropriate administration of antibiotics, as well as a comprehensive approach for dysphagia plays a pivotal role in the prognosis and recovery from ASP. The non-pharmacologic approach, including swallowing rehabilitation and oral care, and a pharmacologic approach including ACE inhibitors and bronchodilators, are essential modalities for treatment and prevention of ASP. The clinical data of NHCAP provides us with a promising treatment strategy for ASP.

Keywords: Animal model; Aspiration pneumonia; Dysphagia; Micro-aspiration; Swallowing function test.

Publication types

  • Review

MeSH terms

  • Aged
  • Animals
  • Community-Acquired Infections*
  • Deglutition Disorders* / epidemiology
  • Deglutition Disorders* / etiology
  • Healthcare-Associated Pneumonia*
  • Humans
  • Models, Animal
  • Pneumonia* / drug therapy
  • Pneumonia* / epidemiology
  • Pneumonia, Aspiration* / drug therapy
  • Pneumonia, Aspiration* / epidemiology
  • Pneumonia, Aspiration* / etiology